CAncer, NUtrition and Taste 2
CANUT-2
Impact of a Nutritional, Sensory and Culinary Support on the Improvement of the Quality of Life Related to Meals in Patients With Cancer Cancer Patients Treated With Chemotherapy
1 other identifier
interventional
209
1 country
10
Brief Summary
Although it has been established that the perception of food and eating and cooking habits change during cancer and its treatment, quality of life related to meals, which is an indicator of the psychobiological and physiological well-being of patients in their relationship to food, has been little studied in the pathological context, and particularly in patients undergoing chemotherapy. Beyond its biological role, food plays a significant psychobiological and social role, as shown by a series of qualitative studies based on interviews with patients. Following a cancer diagnosis, loss of appetite, difficulty in sharing a meal with the family, and reduced pleasure in eating disrupt the patient's relationship with his or her food. Thus, side effects such as fatigue, nausea and vomiting, and alterations in taste and smell induced by chemotherapy will affect patients' eating behavior, increasing the risk of deteriorating their quality of life with food. As these side effects are less known and therefore less expected by patients, they often lack the information and tools necessary to understand them. The present study proposes a support for cancer patients treated by chemotherapy in order to improve their quality of life related to meals, and thus keep the pleasure of eating and reduce the risks of malnutrition. This support will consist of a guide provided to patients, in which they will have information on the functioning of the sensory systems involved in the eating experience, advice and culinary tips to adapt foods to their sensory disorders, and recipes that can be adapted in mild (for patients with hypersensitivity to tastes/smells), accentuated (for patients with hypersensitivity to tastes/smells) and enriched (for patients at risk of denutrition) versions. In addition, their sensory abilities will be assessed at the beginning of the study by psychophysical tests, then between each chemotherapy via a telephone interview (self-reported sensory abilities), and they will benefit from orientation according to the test results. This work will be a first action to improve the quality of life related to the meal by information, follow-up, and adaptation of the meals to the sensory performances of each patient.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable breast-cancer
Started Jan 2022
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 19, 2021
CompletedFirst Posted
Study publicly available on registry
August 30, 2021
CompletedStudy Start
First participant enrolled
January 27, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 21, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 21, 2023
CompletedOctober 11, 2023
October 1, 2023
1.6 years
August 19, 2021
October 9, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
QVA questionnaire score difference between the 2 arms
The main endpoint of CANUT-2 is the comparison of the overall score of the food quality of life questionnaire (Qualité de Vie Alimentaire QVA) between patients who received CANUT support and those who did not receive the CANUT support. The comparison is performed at the time of V2 i.e. after 4 cycles of chemotherapy treatment, corresponding with the end of study follow-up.
At the end of study follow-up, up to 12 weeks
Secondary Outcomes (14)
QVA questionnaire score
At the end of study follow-up, up to 12 weeks
QLQ-C30 score
At the end of study follow-up, up to 12 weeks
Weight
At the end of study follow-up, up to 12 weeks
waist size
At the end of study follow-up, up to 12 weeks
hip size
At the end of study follow-up, up to 12 weeks
- +9 more secondary outcomes
Study Arms (2)
patients receiving CANUT support (guide + dietary interviews)
EXPERIMENTALPatients included in this arm will have following interventions : * CANUT support : patients will receive the CANUT guide (food guide) to help them deal with eating disorders encountered during their chemotherapy treatment ; the CANUT support includes calls from a dietician between chemotherapy cycles for support and advice. * anthropometric measures * Prehension strength measurement * food quality of life questionnaire (Qualité de Vie Alimentaire QVA) * Quality of Life Questionnaire Core 30 (QLQ C30) * Scratch \& Snif Test * Taste Strip Test * Nutrition interview * 24 H feed back questionnaire * condiment questionnaire * tobacco questionnaire
patients not receiving canut support (guide + dietary interviews)
ACTIVE COMPARATORPatients included in this arm will have following interventions : * anthropometric measures * Prehension strength measurement * food quality of life questionnaire (Qualité de Vie Alimentaire QVA) * Quality of Life Questionnaire Core 30 (QLQ C30) * Scratch \& Snif Test * Taste Strip Test * Nutrition interview * 24 H feed back questionnaire * condiment questionnaire * tobacco questionnaire
Interventions
CANUT support includes delivery of the CANUT guide (food guide developed by Paul Bocuse Institute from previous results) ; it will be given to patient with explanations about the use of the guide. This also includes 2 calls from a dietician, performed between the 1st and the 3rd chemotherapy cycle to help patient personally with their food side effects.
These measures include weight, waist size, hip size and brachial circumference
Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
Food quality of life questionnaire
Quality of Life questionnaire Core 30
The Scratch \& Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
This questionnaire describes patient's food and drink intakes during the last 24 ours
This questionnaire used to assess condiments consumption
This questionnaire used to assess tobacco consumption
This interview will be conducted by a dietician
Eligibility Criteria
You may qualify if:
- Major patient with one of the following 3 types of cancer:
- histologically or cytologically proven localized breast cancer cytologically proven
- Gynecological cancer (ovarian cancer or uterine cancer) stage III-IV without functional digestive signs related to the tumor disease
- Patient with a body mass index (BMI) between 18 Kg/m² and 35 Kg/m².
- Patient for whom the indication for treatment with a first line of intravenous chemotherapy (+/- targeted therapy) has been accepted by multidisciplinary meeting.
- Patient naive to previous chemotherapy.
- Life expectancy \> 3 months.
- Patient with written informed consent
- Patient affiliated to a French social security system.
You may not qualify if:
- Patient under 18 years
- Patient who had another malignancy within the last 3 years years, with the exception of carcinoma in situ of the cervix or cervical carcinoma in situ or adequately treated squamous cell carcinoma of the skin adequately treated, or basal cell skin cancer.This cancer must be adequately controlled.
- Patients with symptomatic brain and/or meningeal metastases.
- Patients with symptomatic mucositis.
- Patients suffering or having suffered from an ear, nose and throat disease or oeso-gastro intestinal pathology interfering with the food intake.
- Patients suffering from digestive disorders such as nausea prior to any cancer treatment.
- Indication of concomitant radiotherapy or immunotherapy treatment alone.
- Patients with a known food allergy or intolerance
- Patient with diagnosed partial or total ageusia.
- Patient with diagnosed partial or total anosmia.
- Patient unable to be regularly followed for any reason (geographical, family, social, psychological,...).
- Patient deprived of liberty or placed under guardianship or legal protection.
- Pregnant or breastfeeding woman
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (10)
Hôpital Louis Pradel, Service gynécologie
Bron, 69677, France
Hôpital Louis Pradel, Service pneumologie
Bron, 69677, France
Infirmerie Protestante
Caluire-et-Cuire, 69300, France
Hôpital de la Croix Rousse, service pneumologie
Lyon, 69004, France
Centre Léon Bérard, service gynécologie
Lyon, 69008, France
Centre Léon Bérard, service pneumologie
Lyon, 69008, France
Centre hospitalo-universitaire de Lyon Sud, service Oncologie médicale
Pierre-Bénite, 69310, France
Centre hospitalo-universitaire de Lyon Sud, service pneumologie
Pierre-Bénite, 69310, France
CHU St Etienne,
Saint-Etienne, 42270, France
CH de Valence
Valence, 26 953, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 19, 2021
First Posted
August 30, 2021
Study Start
January 27, 2022
Primary Completion
September 21, 2023
Study Completion
September 21, 2023
Last Updated
October 11, 2023
Record last verified: 2023-10